Asthma

The additional indication for benralizumab was supported by data from the phase 3 TATE trial.

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

Your daily dose of the clinical news you may have missed.

New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.

AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.

AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.

Your daily dose of the clinical news you may have missed.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

Past month use of cannabis was associated with 43% greater odds of asthma than no use of the drug; odds were 2-fold greater with use of blunts.

New data suggest that dupilumab is safe for long-term use among patients with moderate-to-severe asthma or OCS-dependent severe asthma.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.

Use of dupilumab also eliminated the need for use of a rescue inhaler in more than one-third of treated patients and the number of inhalations needed for others.

Your daily dose of the clinical news you may have missed.

A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.

Your daily dose of the clinical news you may have missed.

Many patients with moderate-to-severe asthma may not be using inhaled corticosteroids along with rescue medications to avoid serious disease exacerbations.

Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI; Dareen D. Siri, MD, FAAAAI, FACAAI; Nicole Chase, MD, FAAP, FACAAI, FAAAAI; and Andrew White, MD, give final thoughts on asthma management, considering the current treatment landscape.

Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.

Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.

Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.

Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.

Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.

Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.

Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.

Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.

Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.

Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the tools available to predict the exacerbation of asthma, highlighting spirometry and biomarkers as effective tools.

A panel of experts comment on primary care vs specialist care for patients with asthma, and when patients should be referred to a specialist.